Cancer is currently the second leading cause of death globally and is expected to be
responsible for approximately 9.6 million deaths in 2018. With an unprecedented …

Small molecule covalent kinase inhibitors (CKIs) have entered a new era in drug discovery,
which have the advantage for sustained target inhibition and high selectivity. An increased …

Deregulation of many kinases is directly linked to cancer development and the tyrosine
kinase family is one of the most important targets in current cancer therapy regimens. In this …

A new series of benzimidazole, 1, 2, 4-triazole, and 1, 3, 5-triazine derivatives were
designed and synthesized using a microwave irradiation synthetic approach utilizing 2 …

Purpose: Examination of somatic epidermal growth factor receptor (EGFR) mutations is now
a diagnostic routine for treatment of cancer using EGFR tyrosine kinase inhibitors (EGFR …

Oncolytic viruses are generally designed to be cancer selective on the basis of a single
genetic mutation. JX-594 is a thymidine kinase (TK) gene-inactivated oncolytic vaccinia virus …

Both the first‐generation reversible epidermal growth factor receptor (EGFR) inhibitors
gefitinib and erlotinib and the second‐generation covalent epidermal growth factor receptor …

Covalent ligand-target interactions offer significant pharmacological advantages. However,
off-target reactivity of the reactive groups, which usually have electrophilic properties, must …

The two essential requirements for pathologic specimens in the era of personalized
therapies for non-small cell lung carcinoma (NSCLC) are accurate subtyping as …

Human papillomaviruses (HPV) are small oncogenic DNA viruses of which more than 200
types have been identified to date. A small subset of these is etiologically linked to the …